Health Care · Services-Home Health Care Services

CHE Chemed Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1958495 filings

CHE at a glance

Chemed Corp (CHE, SEC CIK 19584) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Chemed Corp (CHE) reported revenue of $2.5 billion (up 4.1% from FY2024) and net income of $265.2 million. Diluted EPS was $18.34.
  • As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Chemed Corp (CHE) shares worth $3.1 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by LEE SPENCER S on November 11, 2026 of 1,000 shares at $547.61 per share.
  • In the last 90 days, CHE insiders reported 0 open-market purchases ($0) and 5 open-market sales ($4.1M) on Form 4, a net sale of $4.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.5B
+4.1% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$4.1M
13F holders
39 funds
$3.1B · +1 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the latest 10-K and prior 10-Q
  • Carried-forward regulatory, operational, market, and financial risks remain applicable

Management Discussion & Analysis

  • Q3 revenue $690.9M, up 10.6% YoY from $624.9M, led by VITAS up 12.2%
  • Gross margin 33.7% vs 32.0% YoY, adjusted EBITDA margin 19.4% vs 17.4%
  • Best segment VITAS: revenue $457.4M, net income $65.7M, after-tax margin 14.4% vs 11.5%
  • Worst segment Roto-Rooter: net income $30.1M vs $32.1M, after-tax margin 13.0% vs 14.8%
  • Operating cash flow decreased $25.1M; debt rose $236.0M and treasury stock increased $400.0M from repurchases and acquisitions
  • Outlook: no material FY2026 impact expected, but inflation, tariffs, fuel costs and Iran-related fuel pressures threaten future profitability

AI summary of the CHE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026, covering Chemed’s latest operating performance
  • Press release furnished as Exhibit 99, containing the detailed financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $690.9M, up 10.6%; GAAP EPS $5.45, up 22.2%, adjusted EPS $6.75, up 28.1%
  • VITAS drove earnings: revenue $457.4M, ADC up 9.4%, adjusted EBITDA up 31.4% to $92.5M
Filed Jul 28, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Investor-relevant financial details contained in furnished Exhibit 99 press release

Item EX-99.1: Item EX-99.1

  • Q2 revenue $673.3M, up 8.8%; GAAP EPS $5.13, up 43.7%, adjusted EPS $6.06, up 41.9%
  • VITAS drove upside: revenue $443.3M, up 11.9%; adjusted EBITDA $80.6M, up 20.6%, margin 18.2%

AI summaries of CHE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CHE

Don't miss the next CHE filing

  • Alerts as it files. A push when CHE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CHE, by share count.
  • Ask anything. An AI agent that reads every CHE filing and answers with sources.

CHE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LEE SPENCER SGNov 13, 2026-
LEE SPENCER SSellNov 11, 2026$547.61
MCNAMARA KEVIN JSellNov 3, 2026$537.90
LEE SPENCER SSellNov 2, 2026$537.17
Wherley Joel LAOct 20, 2026$512.64
HUTTON THOMAS CAOct 20, 2026$512.64
Witzeman Michael DAOct 20, 2026$512.64
MCNAMARA KEVIN JAOct 20, 2026$512.64

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.4B$2.5B
Operating Income-$366.5M$338.2M
Net Income$272.5M$302.0M$265.2M
Op. Margin-15.1%13.4%
Net Margin-12.4%10.5%
Balance Sheet
Total Assets$1.7B$1.7B$1.5B
Equity-$1.1B$979.4M
ROE-27.0%27.1%
Per Share
EPS$17.93$19.89$18.34
Cash Flow
Operating CF-$417.5M$388.3M
CapEx$56.9M$49.5M$62.8M

Source: XBRL data in Chemed Corp (CHE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CHE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CHE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202639$3.09B
Q2 202638$2.90B
Q1 202638$2.30B
Q4 202535$2.58B
Q3 202536$2.91B
Q2 202535$2.92B
Q1 202536$2.86B
Q4 202431$2.18B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CHE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

10-Q quarterly reports

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 5, 2026--
4Nov 3, 2026--
10-QOct 29, 2026Analysis
8-KOct 27, 2026Analysis-
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 22, 2026--
4Oct 1, 2026--
4Sep 30, 2026--
4Sep 29, 2026--
4Sep 21, 2026--
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 10, 2026--
4Aug 6, 2026--
4Aug 4, 2026--
4Aug 3, 2026--
10-QJul 31, 2026-
8-KJul 28, 2026Analysis-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

CHE SEC filings: frequently asked questions

Are CHE insiders buying or selling?

In the last 90 days, Chemed Corp (CHE) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $4.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CHE stock?

As of September 30, 2026, the largest Chemed Corp (CHE) holders among the 13F filers tracked by SignalX were BlackRock ($733.6 million), AQR Capital Management ($434.2 million), Vanguard Portfolio Management LLC ($432.1 million), Vanguard Capital Management LLC ($296.3 million), State Street Corp ($221.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CHE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Chemed Corp (CHE) reported revenue of $2.5 billion (up 4.1% from FY2024) and net income of $265.2 million. Diluted EPS was $18.34. The figures come from the XBRL data in the 10-K.

What did CHE report in its latest 8-K?

Chemed Corp (CHE) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026, covering Chemed’s latest operating performance.

What are the latest CHE SEC filings?

Chemed Corp (CHE) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on November 16, 2026.

What is CHE's SEC CIK number?

Chemed Corp (CHE)'s SEC Central Index Key (CIK) is 19584. EDGAR lists every CHE filing under that number.

Ask anything about CHE

The research agent reads CHE's filings, financials, insider trades and 13F holders, then answers with sources.